Physiology of weight loss surgery

Surgical Clinics of North America

Volumn 91, Issue 6, 2011, Pages 1149-1161

  Park, Chan W ^a   Torquati, Alfonso ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adipokines; Bariatric surgery; Cytokines; Diabetes; Gastric bypass; Incretins

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; LEPTIN; NEUROPEPTIDE Y; OBESTATIN; PEPTIDE YY;

ANGIOGENESIS; BARIATRIC SURGERY; BODY MASS; CALORIC RESTRICTION; CELL STIMULATION; CLINICAL EFFECTIVENESS; COMORBIDITY; DIARRHEA; DIET; DISEASE SEVERITY; EATING; ENDOCRINE SYSTEM; ENERGY BALANCE; ENERGY EXPENDITURE; EXERCISE; FOLLOW UP; FOOD INTAKE; GASTRECTOMY; GASTRIC BANDING; GASTROINTESTINAL TRACT; GLYCEMIC CONTROL; HEALTH CARE COST; HORMONE DETERMINATION; HORMONE METABOLISM; HORMONE RELEASE; HUMAN; HUNGER; INSULIN RELEASE; INSULIN SENSITIVITY; JEJUNOILEAL BYPASS; KILLER CELL; LIMBIC SYSTEM; LIPID STORAGE; LONG TERM CARE; MALABSORPTION; MALNUTRITION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PATIENT SAFETY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REMISSION; REVIEW; ROUX Y ANASTOMOSIS; SATIETY; SEDENTARY LIFESTYLE; SLEEVE GASTRECTOMY; SOCIOECONOMICS; STOMACH BYPASS; VAGOTOMY; WEIGHT REDUCTION;

BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; GASTRIC BYPASS; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LEPTIN; NEUROPEPTIDE Y; OBESITY, MORBID; PEPTIDE YY; WEIGHT LOSS;

EID: 80455176649     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2011.08.009     Document Type: Review

References (78)

1. Neel J.V. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am J Hum Genet 1962, 14:353-362.
2. Prentice A.M., Hennig B.J., Fulford A.J. Evolutionary origins of the obesity epidemic: natural selection of thrifty genes or genetic drift following predation release?. Int J Obes 2008, 32:1607-1610.
3. Speakman J.B. Thrifty genes for obesity, an attractive but flawed idea, and an alternative perspective: the 'drifty gene' hypothesis. Int J Obes 2008, 32:1611-1617.
4. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303(3):235-241.
5. Sjöström L., Narbro K., Sjöström C.D., et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007, 357(8):741-752.
6. Buchwald H., Avidor Y., Braunwald E., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004, 292(14):1724-1737.
7. DeMaria E.J., Pate V., Warthen M., et al. Baseline data from American Society for Metabolic and Bariatric Surgery-designated bariatric surgery centers of excellence using the bariatric outcomes longitudinal database. Surg Obes Relat Dis 2010, 6(4):347-355.
8. Flum D.R., Belle S.H., King W.C., et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009, 361(5):445-454.
9. Frideman M.N., Sancetta A.J., Magovern G.J. The amelioration of diabetes mellitus following subtotal gastrectomy. Surg Gynecol Obstet 1955, 100(2):201-204.
10. Pories W.J., Swanson M.S., MacDonald K.G., et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995, 222(3):339-350.
11. Power M.L., Schulkin J. Anticipatory physiological regulation in feeding biology: cephalic phase responses. Appetite 2008, 50(2):194-206.
12. Ochner C.N., Kwok Y., Coceicao E., et al. Selective reduction in neural responses to high calorie foods following gastric bypass surgery. Ann Surg 2011, 253(3):502-507.
13. Sakata I., Sakai T. Ghrelin cells in the gastrointestinal tract. Int J Pept 2010, 10.1155/2010/945056.
14. Cummings D.E., Purnell J.Q., Frayo R.S., et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001, 50(8):1714-1719.
15. Diniz Mde F., Azeredo Passos V.M., Diniz M.T. Bariatric surgery and the gut-brain communication-the state of the art three years later. Nutrition 2010, 10:925-931.
16. Cummings D.E., Overduin J. Gastrointestinal regulation of food intake. J Clin Investig 2007, 117:13-23.
17. Hansen T.K., Dall R., Hosoda H., et al. Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol 2002, 56:203-206.
18. Wren A.M., Bloom S.R. Gut hormones and appetite control. Gastroenterology 2007, 132:2116-2157.
19. Marzullo P., Verti B., Savia G., et al. The relationship between active ghrelin levels and human obesity involves alterations in resting energy expenditure. J Clin Endocrinol Metab 2004, 89(2):936-939.
20. Shiiya T., Nakazato M., Mizuta M., et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002, 87(1):240-244.
21. English P.J., Ghatei M.A., Malik I.A., et al. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 2002, 87(6):2984.
22. Tritos N.A., Mun E., Bertkau A., et al. Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. Obes Res 2003, 11(8):919-924.
23. Cummings D.E., Weigle D.S., Frayo R.S., et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002, 346(21):1623-1630.
24. Oliván B., Teixeira J., Bose M., et al. Effect of weight loss by diet or gastric bypass surgery on peptide YY3-36 levels. Ann Surg 2009, 249(6):948-953.
25. Kelishadi R., Hashemipour M., Mohammadifard N., et al. Short- and long-term relationships of serum ghrelin with changes in body composition and the metabolic syndrome in prepubescent obese children following two different weight loss programmes. Clin Endocrinol 2008, 69(5):721-729.
26. Schur E.A., Cummings D.E., Callahan H.S., et al. Association of cognitive restraint with ghrelin, leptin, and insulin levels in subjects who are not weight-reduced. Physiol Behav 2008, 93(4-5):706-712.
27. Morínigo R., Casamitjana R., Moizé V., et al. Short-term effects of gastric bypass surgery on circulating ghrelin levels. Obes Res 2004, 12:1108-1116.
28. Frühbeck G., Rotellar F., Hernández-Lizoain J.L., et al. Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obes Surg 2004, 14:1208-1215.
29. Shak J.R., Roper J., Perez-Perez G.I., et al. The effect of laparoscopic gastric banding surgery on plasma levels of appetite-control, insulinotropic, and digestive hormones. Obes Surg 2008, 18:1089-1096.
30. Faraj M., Havel P.J., Phélis S., et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003, 88:1594-1602.
31. Holdstock C., Engström B.E., Ohrvall M., et al. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 2003, 88:3177-3183.
32. Soares J.B., Leite-Moreira A.F. Ghrelin, des-acyl ghrelin and obestatin: three pieces of the same puzzle. Peptides 2008, 29(7):1255-1270.
33. Dixon A.F., Dixon J.B., O'Brien P.E. Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study. J Clin Endocrinol Metab 2005, 90(2):813-819.
34. Wang Y., Liu J. Plasma ghrelin modulation in gastric band operation and sleeve gastrectomy. Obes Surg 2009, 19(3):357-362.
35. le Roux C.W., Neary N.M., Halsey T.J., et al. Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J Clin Endocrinol Metab 2005, 90(8):4521-4524.
36. Nogueiras R., Wilson H., Perez-Tilve D., et al. The role of the gastrointestinal hormones ghrelin, peptide YY, and glucagon-like peptide-1 in the regulation of energy balance. Energy metabolism and obesity: research and clinical applications 2008, 107-124. Humana Press, Totowa (NJ). P.A. Donohoue (Ed.).
37. Hanson E.S., Dallman M.F. Neuropeptide Y (NPY) may integrate responses of hypothalamic feeding systems and the hypothalamo-pituitary-adrenal axis. J Neuroendocrinol 1995, 7(4):273-279.
38. Dryden S., Pickavance L., Frankish H.M., et al. Increased neuropeptide Y secretion in the hypothalamic paraventricular nucleus of obese (fa/fa) Zucker rats. Brain Res 1995, 690(2):185-188.
39. Kuo L.E., Kitlinska J.B., Tilan J.U., et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007, 13(7):803-811.
40. Erondu N., Gantz I., Musser B., et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006, 4(4):275-282.
41. Whitson B.A., Leslie D.B., Kellogg T.A., et al. Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study. J Surg Res 2007, 141(1):31-39.
42. Ballantyne G.H. Peptide YY(1-36) and peptide YY(3-36): part I. Distribution, release and actions. Obes Surg 2006, 16(5):651-658.
43. Pironi L., Stanghellini V., Miglioli M., et al. Fat-induced ileal brake in humans: a dose-dependent phenomenon correlated to the plasma levels of peptide YY. Gastroenterology 1993, 105(3):733-739.
44. Jayasena C.N., Bloom S.R. Role of gut hormones in obesity. Endocrinol Metab Clin North Am 2008, 37(3):769-788.
45. le Roux C.W., Bloom S.R. Peptide YY, appetite and food intake. Proc Nutr Soc 2005, 64(2):213-216.
46. Beckman L.M., Beckman T.R., Earthman C.P. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review. J Am Diet Assoc 2010, 110(4):571-584.
47. Sloth B., Holst J.J., Flint A., et al. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 2007, 292(4):E1062-E1068.
48. Batterham R.L., Cohen M.A., Ellis S.M., et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003, 349(10):941-948.
49. le Roux C.W., Welbourn R., Werling M., et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007, 246(5):780-785.
50. Korner J., Inabnet W., Febres G., et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes 2009, 33(7):786-795.
51. Karamanakos S.N., Vagenas K., Kalfarentzos F., et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg 2008, 247(3):401-417.
52. Sikaris K.A. The clinical biochemistry of obesity. Clin Biochem 2004, 25(3):165-181.
53. Heymsfield S.B., Greenberg A.S., Fujioka K., et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999, 282(16):1568-1575.
54. Fogteloo A.J., Pijl H., Frölich M., et al. Effects of recombinant human leptin treatment as an adjunct of moderate energy restriction on body weight, resting energy expenditure and energy intake in obese humans. Diabetes Nutr Metab 2003, 16(2):109-114.
55. Zelissen P.M., Stenlof K., Lean M.E., et al. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes Obes Metab 2005, 7(6):755-761.
56. Ram E., Vishne T., Maayan R., et al. The relationship between BMI, plasma leptin, insulin and proinsulin before and after laparoscopic adjustable gastric banding. Obes Surg 2005, 15(10):1456-1462.
57. Kotidis E.V., Koliakos G.G., Baltzopoulos V.G., et al. Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatment-a prospective study. Obes Surg 2006, 16(11):1425-1432.
58. Pardina E., Ferrer R., Baena-Fustegueras J.A., et al. The relationships between IGF-1 and CRP, NO, leptin, and adiponectin during weight loss in the morbidly obese. Obes Surg 2010, 20(5):623-632.
59. Centers for Disease Control and Prevention National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 2011, US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta (GA).
60. American Diabetes Association Standards of medical care in diabetes - 2011. Diabetes Care 2011, 34(Suppl 1):S11-S61.
61. Bose M., Teixeira J., Olivan B., et al. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes 2010, 2(1):47-55.
62. Laferrère B. Effect of gastric bypass surgery on the incretins. Diabetes Metab 2009, 35(6 Pt 2):513-517.
63. Kashyap S.R., Daud S., Kelly K.R., et al. Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes 2010, 34(3):462-471.
64. Isbell J.M., Tamboli R.A., Hansen E.N., et al. The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery. Diabetes Care 2010, 33(7):1438-1442.
65. Efendic S., Portwood N. Overview of incretin hormones. Horm Metab Res 2004, 36(11-12):742-746.
66. Rao R.S., Kini S. GIP and bariatric surgery. Obes Surg 2011, 21(2):244-252.
67. Theodorakis M.J., Carlson O., Muller D.C., et al. Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance. Diabetes Care 2004, 27(7):1692-1698.
68. Hickey M.S., Pories W.J., MacDonald K.G., et al. A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut?. Ann Surg 1998, 227:637-643.
69. Rubino F., Forgione A., Cummings D.E., et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006, 244:741-749.
70. Laferrère B., Heshka S., Wang K., et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007, 30(7):1709-1716.
71. Doyle M.E., Egan J.M. Glucagon-like peptide-1. Recent Prog Horm Res 2001, 56:377-399.
72. Thomas S., Schauer P. Bariatric surgery and the gut hormone response. Nutr Clin Pract 2010, 25(2):175-182.
73. Barber T.M., Begbie H., Levy J. The incretin pathway as a new therapeutic target for obesity. Maturitas 2010, 67(3):197-202.
74. Peterli R., Wölnerhanssen B., Peters T., et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 2009, 250(2):234-241.
75. Pournaras D.J., Osborne A., Hawkins S.C., et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg 2010, 252(6):966-971.
76. Dixon J.B., O'Brien P.E., Playfair J., et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008, 299(3):316-323.
77. Piya M.K., Tahrani A.A., Barnett A.H. Emerging treatment options for type 2 diabetes. Br J Clin Pharmacol 2010, [Epub ahead of print]. 10.1111/j.1365-2125.2010.03711.x.
78. Deitel M. Update: why diabetes does not resolve in some patients. Obes Surg 2011, 21(6):794-796.